Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site 12
North Little Rock, Arkansas, United States
- Site 4
Rolling Meadows, Illinois, United States
- Site 7
Plainfield, Indiana, United States
- Site 11
Baton Rouge, Louisiana, United States
- Site 13
New Orleans, Louisiana, United States
- Site 10
Minneapolis, Minnesota, United States
- Site 9
New Brighton, Minnesota, United States
- Site 3
Portland, Oregon, United States
- Site 5
Knoxville, Tennessee, United States
- Site 8
Murfreesboro, Tennessee, United States
- Site 1
Austin, Texas, United States
- Site 6
College Station, Texas, United States
- Site 2
Norfolk, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Mar 2023
- Primary completion
- 8 Nov 2023
- Completion
- 29 Jan 2024
- Last update posted
- 12 Nov 2025
- Registered enrollment
- 71
- Registry id
- NCT05802173
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.